High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration
Spinocerebellar Degenerations
About this trial
This is an interventional treatment trial for Spinocerebellar Degenerations focused on measuring Ataxia, Treatment, IVIG, SCA, Cerebellar Degeneration, Cerebellar Ataxia, Cerebellum
Eligibility Criteria
INCLUSION CRITERIA: Adults over 18 with hereditary or sporadic cerebellar degeneration. Sporadic cerebellar degeneration may include the cerebellar predominant variant of Multiple System Atrophy (MSA-C). Hereditary ataxia is limited to the SCAs (spinocerebellar ataxias) or those patients with clear autosomal dominant ataxia. Patients must also have evidence for an immune component to their condition such as gluten-sensitivity or antiganglioside antibodies. EXCLUSION CRITERIA: Patients on the gluten-free diet. Those who wish to participate in this trial must be off the diet for a period of 3 months prior to the start of the study. Patients with Friedreich's ataxia. To date, this has not been associated with autoimmune phenomena. We would not expect this population to respond. Patients with other autosomal recessive and mitochondrial forms of ataxia, since autoimmunity has not been studied in this population. Patients with hypercoaguable disorders. This includes conditions like Protein C or S deficiency, underlying malignancy and/or paraproteinemia. Patient with acute renal insufficiency or patients on known nephrotoxic drugs. Patients with selective IgA deficiency Known paraneoplastic cerebellar degeneration. Cerebellar ataxia that is congenital, static and/or symptomatic (due to stroke, tumor, demyelinating or infectious). Women who are pregnant or lactating. Those of child-bearing age will be asked to use effective contraception for the duration of the study. Those patients who do not wish to use a product derived from human serum (for example, Jehovah's Witness).
Sites / Locations
- National Institute of Neurological Disorders and Stroke (NINDS)